More states roll out free infant RSV immunisation
The TGA approved the long-acting monoclonal antibody nirsevimab (Beyfortus) in November 2023.
Newborns in Queensland and NSW will be eligible for a free dose of nirsevimab, the newly registered respiratory syncytial virus prophylaxis, under new immunisation programs this winter.
From April, more than 70,000 infants in Queensland will be offered the long-acting monoclonal antibody nirsevimab (Beyfortus) under a $31 million statewide program.
